Celltrion Invests Additional 516.1M USD in Subsidiary Celltrion USA
Celltrion corrects total investment in its 100% subsidiary Celltrion USA to USD 516.1M (approx. 758.9B won), finalizing second payment date on May 13, 2026
Purpose: to fund acquisition of US raw material drug facility and operating expenses
First tranche: USD 445.8M (Dec 18, 2025), second tranche: USD 70.3M (May 13, 2026)
Post-acquisition ownership: 100%, representing 4.32% of Celltrion's equity
Subsidiary (FY2024): assets 517.3B won, net income 3.64B won
KOSPI Filing Information
[Correction of Description] Decision on Acquisition of Stocks and Equity Securities of Other Corporations